Fluzone High-Dose Quadrivalent PF 2022-2023 was administered by a healthcare professional. Proper preparation and injection technique were essential for its safe and effective delivery.

• Preparation: The vaccine was supplied as a colorless to slightly opalescent suspension for injection in a prefilled syringe. Before administration, the syringe should have been visually inspected for particulate matter or discoloration. If present, the vaccine should not have been administered. The syringe was gently shaken before use.
• Administration Route: The vaccine was administered intramuscularly, preferably into the deltoid muscle. Intravenous administration was contraindicated.
• Single-Dose: Each syringe contained a single 0.7 mL dose.
• One Annual Dose: Typically, only one dose was required for the entire influenza season.
• Post-Vaccination Monitoring: As with all injections, recipients were often advised to remain at the vaccination site for 15 minutes after administration to monitor for immediate allergic reactions or vasovagal syncope (fainting).
• Storage: The vaccine needed to be stored refrigerated between 2° to 8°C (35° to 46°F) and should not have been frozen, as freezing could denature the antigens and render the vaccine ineffective.

Fluzone High-Dose Quadrivalent PF 2022-2023 works by stimulating the body’s immune system to produce protective antibodies against the influenza viruses contained in the vaccine. Since older adults often have a less robust immune response to standard-dose flu vaccines, the higher antigen content of Fluzone High-Dose was specifically engineered to overcome this.

• Antigen Presentation: The vaccine contains inactive (killed) influenza virus components, specifically the hemagglutinin (HA) protein, from four different strains. When injected, these antigens are recognized by the body as foreign.
• Immune System Activation: The immune system’s cells (like B-cells and T-cells) identify these antigens. B-cells are stimulated to produce antibodies that specifically target the influenza viruses. T-cells also become activated, helping to mount a stronger cellular immune response.
• Higher Antigen Load: The “High-Dose” aspect means it contained four times the amount of antigen (60 mcg of HA per strain, totaling 240 mcg) compared to standard quadrivalent flu vaccines (15 mcg of HA per strain, totaling 60 mcg). This higher dose is intended to provide a more potent stimulus to the aging immune system, leading to a greater quantity and quality of antibodies.
• Antibody Production: It takes about two weeks after vaccination for the body to develop sufficient protective antibodies. These antibodies circulate in the bloodstream, ready to recognize and neutralize the actual influenza virus if the vaccinated person is exposed.
• Prevention of Infection/Severity: If exposed to one of the vaccine strains, the pre-existing antibodies can prevent infection or significantly reduce the severity of the illness, thus lowering the risk of complications, hospitalization, and death.

Like all vaccines, Fluzone High-Dose Quadrivalent PF 2022-2023 could cause side effects, although most were mild and temporary. Serious side effects were rare.

• Common Local Side Effects (at injection site):
  • Pain, tenderness, redness (erythema), swelling, or hardening (induration). These were generally mild to moderate and resolved within a few days.
  • Bruising.
• Common Systemic Side Effects:
  • Headache.
  • Muscle aches (myalgia).
  • Feeling unwell (malaise).
  • Fatigue.
  • Nausea, vomiting, or diarrhea.
  • Fever or chills.
• Serious Side Effects (Rare):
  • Severe Allergic Reaction (Anaphylaxis): This is rare but can occur within minutes to hours of vaccination. Symptoms include hives, swelling of the face/throat, difficulty breathing, dizziness, or weakness. Medical supervision is crucial during and immediately after vaccination to manage such reactions.
  • Guillain-Barré Syndrome (GBS): GBS is a rare neurological disorder. While a causal link between GBS and seasonal influenza vaccines is inconclusive, if an excess risk exists, it is very small (about 1 additional case per million vaccinated persons). Individuals with a history of GBS within 6 weeks of a previous flu vaccination should discuss the risks and benefits with their doctor.
  • Syncope (Fainting): Can occur immediately after an injection, often as a psychogenic response to the needle.
  • Neurological disorders: Very rarely, conditions like encephalomyelitis, transverse myelitis, or brachial neuritis have been reported.
• Report any persistent, severe, or unusual side effects to a healthcare provider.

Several important warnings and precautions were associated with the administration of Fluzone High-Dose Quadrivalent PF 2022-2023 to ensure patient safety.

• Allergic Reactions: Do not administer to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine. Healthcare providers should have appropriate medical treatment readily available to manage severe allergic reactions.
• Guillain-Barré Syndrome (GBS): As mentioned, individuals who have experienced GBS within 6 weeks following a previous influenza vaccination should have the decision to vaccinate based on careful consideration of potential benefits and risks.
• Altered Immunocompetence: Immunocompromised individuals, including those receiving immunosuppressive therapy (e.g., high-dose corticosteroids, chemotherapy, certain biologic agents), may have a lower immune response to the vaccine.
• Acute Illness: Vaccination should be postponed in individuals with an acute illness accompanied by a moderate or high fever. A minor illness (e.g., cold) without fever is usually not a reason to postpone vaccination.
• Limitations of Vaccine Effectiveness: No vaccine is 100% effective. Vaccination may not protect all recipients, particularly if the circulating strains do not closely match those in the vaccine.

Egg Allergy: While the vaccine contains traces of egg protein due to its manufacturing process, current guidelines (including those from the CDC for the 2022-2023 season) state that persons with egg allergy of any severity may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status. However, those with a history of severe allergic reaction to egg (e.g., angioedema, respiratory distress) should be vaccinated in a medical setting supervised by a healthcare provider who is able to manage severe allergic reactions.

•  Vaccines typically have fewer drug-drug interactions compared to systemic medications. However, certain considerations are important:
  • Immunosuppressive Therapy: If administered to immunocompromised persons, including those receiving immunosuppressive therapy (e.g., corticosteroids, chemotherapy), the immune response to the vaccine may be lower than expected, potentially leading to reduced protection.
  • Other Vaccines: Fluzone High-Dose Quadrivalent can generally be co-administered with other vaccines (e.g., COVID-19 vaccines, Pneumococcal vaccines) on the same day, but it’s important to administer them at different injection sites. Always consult healthcare guidelines for co-administration.
• It is always important to inform the healthcare provider about all current medications, medical conditions, and any history of allergic reactions.

The dosage guidelines for Fluzone High-Dose Quadrivalent PF 2022-2023 were simple and consistent for its target demographic, reflecting the goal of providing optimal protection with a single annual dose.

• Target Population: The vaccine was specifically indicated and studied for use in persons 65 years of age and older.
• Single Annual Dose: The recommended dosage was a single 0.7 mL intramuscular injection per influenza season. This single shot provided protection for the entire flu season.
• No Fractional Dosing: It was critical not to administer fractional doses. The prefilled syringe contained the exact 0.7 mL dose, minimizing potential for error.
• Timely Vaccination: Vaccination should ideally occur before the peak of influenza activity in the community, typically in the fall, to allow sufficient time for the immune response to develop. However, vaccination efforts continued throughout the flu season as long as influenza viruses were circulating.
• Consistency: Adherence to annual vaccination was paramount because influenza viruses constantly evolve, and vaccine formulations are updated each year to match the predicted circulating strains.

Fluzone High-Dose Quadrivalent PF 2022-2023 was a prescription-only biological product (vaccine). It was administered by qualified healthcare professionals and was not available for self-administration.

• Medical Oversight: The administration of Fluzone High-Dose Quadrivalent required oversight by a licensed healthcare provider (physician, nurse, pharmacist, etc.) due to the need for proper injection technique, monitoring for immediate adverse reactions, and adherence to vaccination guidelines.
• Not an OTC Product: Unlike some over-the-counter medications, vaccines like Fluzone High-Dose were not available for direct purchase by the public without involvement of the healthcare system.
• Public Health Programs: In many regions, influenza vaccination is often part of public health campaigns, allowing eligible individuals to receive the vaccine at clinics, pharmacies, or doctor’s offices, usually covered by health insurance or public health initiatives.
• Record Keeping: Healthcare providers maintained detailed records of vaccination, including the vaccine type, lot number, administration date, and the person who administered it, for public health tracking and patient safety.

1. What is this vaccine used for? To prevent seasonal influenza in adults aged 65 and older.

2. What type of vaccine is it? Inactivated influenza virus vaccine (quadrivalent, high-dose).

3. What strains are included in the 2022–2023 version? Two influenza A strains and two influenza B strains selected by WHO for the 2022–2023 flu season.

4. What makes it “high-dose”? It contains 60 mcg of hemagglutinin antigen per strain, four times the amount in standard-dose flu vaccines.

5. What age group is it approved for? Adults aged ≥65 years.

6. What is the dosage and route? 0.7 mL intramuscular injection, typically in the deltoid muscle.

7. Is it a live vaccine? No, it is an inactivated (non-live) vaccine.

8. What are common side effects? Injection site pain, muscle aches, headache, and fatigue.

9. Can it cause serious reactions? Rarely—allergic reactions, Guillain-Barré syndrome, or fever.

10. Is it safe during pregnancy? Not indicated for pregnant individuals; intended for older adults.

11. Is a prescription required? Yes, administered by healthcare professionals.

12. Is it available in Pakistan? Availability may vary; check with hospitals or immunization centers.

13. Can it be used with other vaccines? Yes, but spacing may be recommended depending on the vaccine.

14. How long does protection last? Typically 6–12 months; annual vaccination is recommended.

15. What makes it different from regular Fluzone? Higher antigen dose and stronger immune response in older adults.

16. Is it used for COVID-19 prevention? No, it only protects against influenza.

17. Can it be used in immunocompromised patients? Yes, but consult a healthcare provider.

18. What should be avoided after vaccination? Monitor for allergic reactions; no specific activity restrictions.

19. Is it part of routine immunization? Yes, for seniors during flu season.

20. What does “PF” mean? Preservative-free formulation.